The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis.

IF 2.4 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Current Cardiology Reviews Pub Date : 2025-02-13 DOI:10.2174/011573403X345749250122092324

Rubela Ray, Arhum Mahmood, Raheel Chaudhry, Mohd Diya Masmoum, Muhammad Talha, Fahad I Siddiqui, Imdad Ullah

{"title":"The Impact of Novel Lipid-Lowering Agents on Cardiovascular Risk Reduction: A Systematic Review and Meta-Analysis.","authors":"Rubela Ray, Arhum Mahmood, Raheel Chaudhry, Mohd Diya Masmoum, Muhammad Talha, Fahad I Siddiqui, Imdad Ullah","doi":"10.2174/011573403X345749250122092324","DOIUrl":null,"url":null,"abstract":"Introduction: Reducing the risk of atherosclerotic cardiovascular disease is the aim of lipid-lowering therapy (ASCVD). It is commonly acknowledged that low-density lipoprotein (LDL) is a major cause of ASCVD. Several online databases and search engines, such as Pub- Med and the Cochrane Library, were used to conduct a thorough search.Method: This study included RCTs assessing the effect of PCSK9 inhibitors on cardiovascular events. The RevMan 5.4 software was used to conduct the meta-analysis. This analysis included nine RCTs in total.Results: Meta-analysis of the included studies showed that the levels of total cholesterol, LDL, and triglycerides were reduced after the use of PCSK9 inhibitors, and HDL levels were increased, which is good cholesterol. Most adverse cardiac events (MACE) were reduced after the use of PCSK9 inhibitors.Conclusion: In conclusion, ezetimibe, a PCSK9 inhibitor added to statin therapy, further reduces MACE risk without affecting all-cause mortality, even though statins already significantly reduce major adverse cardiovascular events (MACE) and mortality.","PeriodicalId":10832,"journal":{"name":"Current Cardiology Reviews","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Cardiology Reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/011573403X345749250122092324","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Reducing the risk of atherosclerotic cardiovascular disease is the aim of lipid-lowering therapy (ASCVD). It is commonly acknowledged that low-density lipoprotein (LDL) is a major cause of ASCVD. Several online databases and search engines, such as Pub- Med and the Cochrane Library, were used to conduct a thorough search.

Method: This study included RCTs assessing the effect of PCSK9 inhibitors on cardiovascular events. The RevMan 5.4 software was used to conduct the meta-analysis. This analysis included nine RCTs in total.

Results: Meta-analysis of the included studies showed that the levels of total cholesterol, LDL, and triglycerides were reduced after the use of PCSK9 inhibitors, and HDL levels were increased, which is good cholesterol. Most adverse cardiac events (MACE) were reduced after the use of PCSK9 inhibitors.

Conclusion: In conclusion, ezetimibe, a PCSK9 inhibitor added to statin therapy, further reduces MACE risk without affecting all-cause mortality, even though statins already significantly reduce major adverse cardiovascular events (MACE) and mortality.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

简介降低动脉粥样硬化性心血管疾病的风险是降脂治疗（ASCVD）的目的。人们普遍认为，低密度脂蛋白（LDL）是导致动脉粥样硬化性心血管疾病的主要原因。本研究利用 Pub- Med 和 Cochrane Library 等多个在线数据库和搜索引擎进行了全面检索：本研究包括评估 PCSK9 抑制剂对心血管事件影响的 RCT。使用RevMan 5.4软件进行荟萃分析。该分析共纳入了九项 RCT：对纳入研究的荟萃分析表明，使用 PCSK9 抑制剂后，总胆固醇、低密度脂蛋白和甘油三酯的水平降低，高密度脂蛋白（即好胆固醇）的水平升高。使用 PCSK9 抑制剂后，大多数心脏不良事件（MACE）都有所减少：总之，在他汀类药物治疗的基础上添加依折麦布（一种PCSK9抑制剂）可进一步降低MACE风险，但不会影响全因死亡率，尽管他汀类药物已能显著降低主要不良心血管事件（MACE）和死亡率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Cardiology Reviews CARDIAC & CARDIOVASCULAR SYSTEMS-

CiteScore

3.70

自引率

10.50%

发文量

117

期刊介绍： Current Cardiology Reviews publishes frontier reviews of high quality on all the latest advances on the practical and clinical approach to the diagnosis and treatment of cardiovascular disease. All relevant areas are covered by the journal including arrhythmia, congestive heart failure, cardiomyopathy, congenital heart disease, drugs, methodology, pacing, and preventive cardiology. The journal is essential reading for all researchers and clinicians in cardiology.